Group 1 - The core viewpoint of the article highlights that Yunnan Betaini Biotechnology Group Co., Ltd. has successfully obtained authorization for two biotechnology patents related to the fermentation applications of a specific yeast strain and a Bacillus subtilis strain [1] - The Bacillus subtilis strain is derived from the Qingci fruit found in the Haba Snow Mountain of Yunnan, which is a key ingredient in the company's skincare brand "Winona" [1] - The company has achieved industrial application upgrades for three significant raw materials derived from Qingci fruit: Qingci fruit oil, polysaccharides, and flavonoids, which are now utilized in various Winona product lines [1] Group 2 - Qingci fruit oil is applied across the entire Winona product range, while Qingci fruit polysaccharides are used in the second generation of the star product, the special care cream [1] - Qingci fruit flavonoids are incorporated into Winona's anti-aging product line, specifically in the Silver Core Cream, thereby redefining the anti-aging standards for sensitive skin [1]

Core Viewpoint - The article highlights the strategic transformation of Yunnan Betaini Biotechnology Group Co., Ltd. (Betaini) in response to the changing dynamics of the Chinese cosmetics industry, focusing on long-term value and quality improvement rather than short-term scale growth [1][4][22]. Financial Performance - In the first half of 2025, Betaini achieved operating revenue of 2.372 billion yuan and a net profit attributable to shareholders of 247 million yuan, reflecting resilience amid industry challenges [1]. - The company reported a significant improvement in operating cash flow, reaching 347 million yuan, a year-on-year increase of 145.70%, indicating strong cash flow management [4][6]. - The gross profit margin remained stable, with an overall gross margin of 76.01% in the first half of 2025, showcasing strong profitability and operational efficiency [13]. Strategic Adjustments - Betaini is actively shifting its strategy from pursuing short-term growth to focusing on quality enhancement and structural optimization, which is evident in its reduced reliance on ineffective promotional activities and price competition [4][6]. - The company has optimized its inventory management, improving inventory turnover and focusing on core product categories, laying a solid foundation for future growth [6][11]. Brand and Market Positioning - Betaini has established a clear brand matrix covering various market segments, from high-end anti-aging to mass skincare, with its main brand, Winona, leading the sensitive skin care market in China [7][9]. - The company has successfully activated differentiated market segments, with brands like Aikeman showing a revenue increase of 93.90% year-on-year, indicating strong growth momentum [9]. Research and Development - Betaini has increased its R&D investment, with a research expense ratio of 4.91%, up 0.83 percentage points from the previous year, positioning itself as a leader in the industry [13][14]. - The company has built a comprehensive R&D chain, focusing on basic research and raw material development, which is expected to create a sustainable competitive advantage [14][16]. Operational Strategy - The company is refining its channel strategy, enhancing online marketing efficiency and expanding its offline presence to over 120,000 pharmacies, while also implementing a "BA content" strategy to deepen user engagement [17][18]. - Betaini is expanding its global footprint, particularly in Southeast Asia, focusing on brand building and local adaptation, which is crucial for its international growth [18][20]. Sustainability and ESG Practices - Betaini integrates ESG principles into its operations, achieving high ratings in environmental, social, and governance aspects, which enhances its brand differentiation and aligns with consumer values [20][22]. - The company is building a resilient and sustainable growth model through channel optimization, global expansion, and ESG initiatives, preparing for a potential recovery in performance in the latter half of 2025 [20][22].

Core Viewpoint - Yunnan Betaini Biotech Group Co., Ltd. reported a resilient performance in the first half of 2025 despite challenges in the cosmetics industry, focusing on long-term value and quality improvement rather than short-term growth [1][2] Group 1: Financial Performance - In the first half of 2025, the company achieved operating revenue of 2.372 billion yuan and a net profit attributable to shareholders of 247 million yuan [1] - The operating cash flow reached 347 million yuan, representing a year-on-year increase of 145.70%, indicating significant improvement in cash return capabilities [2] - The gross profit margin remained stable, and inventory structure continued to improve, reflecting effective management of operational efficiency [1][2] Group 2: Strategic Transformation - The cosmetics industry is undergoing a shift from marketing-driven growth to product-driven and value-driven competition, prompting the company to adjust its strategy for quality enhancement and structural optimization [2] - The company is focusing on long-term value by restructuring product barriers through R&D and enhancing operational efficiency via refined channel management [1][2] Group 3: R&D and Innovation - The company increased its R&D investment, with a research expense ratio of 4.91%, up by 0.83 percentage points year-on-year, positioning it as a leader in the industry [3] - Betaini is deepening its "industry-university-research-medical" collaborative innovation mechanism, establishing a comprehensive R&D chain covering basic research, raw material development, formulation innovation, and clinical evaluation [3] - The company has registered 4 new raw materials in the first half of 2025, bringing the total to 16, which is expected to create a technological moat [3][4]

Core Viewpoint - Yunnan Betaini Biotechnology Group Co., Ltd. (hereinafter referred to as "the company") demonstrated strong operational resilience in the first half of 2025, achieving revenue of 2.372 billion yuan and net profit of 247 million yuan despite challenges in the cosmetics industry, which is transitioning from "scale expansion" to "high-quality development" [1][2]. Financial Performance - The company reported a significant improvement in operating cash flow, reaching 347 million yuan, a year-on-year increase of 145.70%, with Q2 cash flow netting 416 million yuan, indicating enhanced cash return capabilities [2][3]. - The overall gross margin for the first half of 2025 was 76.01%, reflecting strong profitability and operational efficiency [5]. Strategic Adjustments - The company is actively pursuing a strategic transformation focused on long-term value, shifting from short-term scale growth to quality enhancement and structural optimization [1][2]. - By controlling ineffective promotional activities and reducing price competition, the company successfully improved its gross margin, demonstrating an accurate understanding of industry trends [2][3]. Inventory and Accounts Receivable Management - The company improved its inventory turnover rate and effectively managed accounts receivable, with 96.02% of accounts aged within one year, maintaining a reasonable bad debt provision ratio of 5.29% [3]. - The optimization of working capital structure has enhanced liquidity, providing ample resources for future R&D investments and market expansion [3]. R&D Investment - The company increased its R&D expense ratio to 4.91%, up 0.83 percentage points year-on-year, maintaining a leading position in the industry [4][5]. - The establishment of a comprehensive R&D chain covering basic research, raw material development, formulation innovation, and clinical evaluation is a key focus for the company [5]. Brand and Market Positioning - The main brand, Winona, continues to lead the sensitive skin care market in China, with significant sales achievements and recognition as a top brand [8][9]. - The company has developed a multi-brand matrix that covers various market segments, enhancing brand value and achieving strong growth in different product lines [9][10]. Global Expansion and ESG Practices - The company is deepening its global presence, particularly in Southeast Asia, while focusing on brand building and local adaptation [12][13]. - The integration of ESG principles into operations has led to high ratings from domestic agencies, establishing the company as a leader in environmental, social, and governance practices [12][13]. Future Outlook - With inventory optimization and new product capacity release, the company is expected to experience a performance recovery in the second half of 2025 [13]. - The strategic shift towards long-term value creation positions the company well for sustainable growth in the evolving cosmetics industry [13].

Core Viewpoint - Yunnan Betaini Biotechnology Group Co., Ltd. plans to use part of its raised funds to temporarily supplement working capital, addressing a temporary cash flow gap due to market changes [1][2]. Fundraising and Usage - The company raised a total of 3,636 million shares at a price of 47.33 yuan per share, totaling 3,010 million yuan, with a net amount of 2,884 million yuan after deducting issuance costs [1]. - The total investment for projects funded by the raised capital is 1,535 million yuan, with excess funds amounting to 1,349 million yuan [1]. - Previous arrangements for the use of excess funds include: - 2021: 400 million yuan for permanent working capital [2]. - 2023: Up to 320 million yuan for temporary working capital, fully repaid by August 8, 2024 [2]. - 2024: 360 million yuan for the "Betaini Central Factory Phase II Project" [2]. - 2024: Up to 320 million yuan for temporary working capital, fully repaid by August 14, 2025 [2]. - 2025: Up to 700 million yuan of idle raised funds and 2,500 million yuan of idle self-owned funds for cash management [2]. - As of August 14, 2025, the balance of excess funds was 325 million yuan, with 340 million yuan allocated for cash management [2]. Board Approval and Compliance - The proposal to use up to 320 million yuan of excess funds for temporary working capital has been reviewed and approved by the audit committee and independent directors, confirming compliance with relevant regulations [3]. - The sponsoring institution, Guosen Securities Co., Ltd., has no objections to this matter [3].

Core Viewpoint - Beitaini's 2025 semi-annual report shows resilience in operations despite challenges in the cosmetics industry, with significant improvements in cash flow and inventory management [1][2] Financial Performance - In the first half of 2025, Beitaini achieved operating revenue of 2.372 billion yuan and net profit attributable to shareholders of 247 million yuan [1] - Operating cash flow reached 347 million yuan, a year-on-year increase of 145.70%, with Q2 cash flow netting 416 million yuan, indicating enhanced cash return capability [1][2] - The overall gross profit margin for the first half of 2025 was 76.01%, reflecting strong profitability and operational efficiency [2] Industry Context - The cosmetics industry in China is transitioning from "scale expansion" to "high-quality development," facing challenges of demand slowdown and intensified competition [1] - Companies are shifting growth strategies from external expansion to internal optimization, with a focus on improving operational efficiency [1] Inventory and Accounts Receivable Management - Beitaini effectively managed inventory turnover and accounts receivable, with 96.02% of accounts aged within one year and a reasonable bad debt provision rate of 5.29% [2] - The overall working capital structure has been optimized, maintaining ample liquidity [2] Research and Development - Despite short-term revenue pressures, Beitaini increased R&D investment, with an R&D expense ratio of 4.91%, up 0.83 percentage points year-on-year, maintaining industry leadership [2] Brand Performance - The main brand, Winona, continues to lead the sensitive skin care market in China, recognized as the top seller in sensitive skin care products for five consecutive years [3] - Beitaini's multi-brand matrix is maturing, with significant revenue growth from brands like Aikeman and Winona Baby, indicating successful activation of differentiated market segments [3] Global Expansion Strategy - Beitaini is focusing on deepening its presence in Southeast Asia and leveraging the Belt and Road Initiative for product registration and local operations [4] - The company emphasizes brand building and local adaptation, with products entering mainstream channels and establishing brand recognition through social media platforms [4]

Core Viewpoint - Betaini's 2025 semi-annual report shows a revenue of 2.372 billion yuan, with a stable gross margin increase to 76.01% [1] Group 1: Financial Performance - The company achieved a revenue of 2.372 billion yuan [1] - The gross margin improved to 76.01% [1] Group 2: Strategic Focus - The company is focusing on strategic adjustments, reducing ineffective investments, and emphasizing research and development along with high-margin products [1] - Cash flow has significantly improved, and inventory structure has been optimized [1] Group 3: Growth and Market Position - The multi-brand matrix has shown impressive growth, with refined channel strategies and steady global expansion [1] - Short-term performance pressures do not diminish the long-term value, as the company strengthens recovery foundations through research and operational efficiency [1]

证券代码：300957 证券简称：贝泰妮 公告编号：2025-037 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 云南贝泰妮生物科技集团股份有限公司（以下简称"公司"）于2025年8月 26日召开了第三届董事会第二次会议审议通过了《关于使用部分超募资金暂时 补充流动资金的议案》。现将有关情况公告如下： 经中国证券监督管理委员会《关于同意云南贝泰妮生物科技集团股份有限 公司首次公开发行股票注册的批复》（证监许可[2021]546号）同意注册，公司 首次公开发行人民币普通股（A股）6,360万股，每股面值1元，每股发行价格为 人民币47.33元，募集资金总额为人民币3,010,188,000元，扣除相关发行费用后实 际募集资金净额为人民币2,883,896,774.95元。募集资金已于2021年3月22日划至 公司指定账户，上述募集资金到位情况经天衡会计师事务所（特殊普通合伙） 进行了审验，并出具"天衡验字（2021）第00024号"《云南贝泰妮生物科技集团 股份有限公司验资报告》。公司已对募集资金进行了专户存储，并与保荐机构、 专户银行分别签订了募集资金三 ...

（一）实际募集资金金额及到账时间 经中国证券监督管理委员会《关于同意云南贝泰妮生物科技集团股份有限公司首次公 开发行股票注册的批复》（证监许可[2021]546 号）同意注册，云南贝泰妮生物科技集团股 份有限公司（以下简称"公司"或"本公司"）首次公开发行人民币普通股（A 股）6,360.00 万股，每股面值 1.00 元，每股发行价格为人民币 47.33 元，募集资金总额为人民币 301,018.80 万元，扣除相关发行费用后实际募集资金净额为人民币 288,389.68 万元。募集 资金已于 2021 年 3 月 22 日划至公司指定账户，上述募集资金到位情况已经天衡会计师事务 所（特殊普通合伙）审验，并出具了《验资报告》（天衡验字（2021）第 00024 号）。 （二）2025年上半年募集资金使用及结余情况 公司募集资金扣除保荐及承销费用初始到账净额为人民币 290,533.14 万元，募集资金 净额人民币 288,389.68 万元。截至 2025 年 6 月 30 日，公司累计已使用募集资金人民币 196,741.42 万元。截至 2025 年 6 月 30 日，本公司募集资金使用及余额情况如下： ...

证券代码：300957 证券简称：贝泰妮 公告编号：2025-036 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 云南贝泰妮生物科技集团股份有限公司（以下简称"公司"）于2025年8月 26日召开了第三届董事会第二次会议审议通过了《关于使用自有资金支付募投 项目人员费用并以募集资金等额置换的议案》。现将有关情况公告如下： 《上市公司募集资金监管规则》第十五条第二款规定："募集资金投资项 目实施过程中，原则上应当以募集资金直接支付，在支付人员薪酬、购买境外 产品设备等事项中以募集资金直接支付确有困难的，可以在以自筹资金支付后 六个月内实施置换。"公司在二期项目实施过程中存在上述以超募资金直接支 付确有困难的情形，主要如下： （一）募集资金的基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意云南 贝泰妮生物科技集团股份有限公司首次公开发行股票注册的批复》（证监许可 [2021]546号）同意注册，云南贝泰妮生物科技集团股份有限公司（以下简称" 公司"）首次公开发行人民币普通股（A股）6,360万股，每股面值1元，每股发 行价格为人民币47 ...